Medication Initiation Burden Required to Comply with Heart Failure Guideline Recommendations and Hospital Quality Measures

Running title: Allen et al.; Heart Failure Medication Initiation Burden

Larry A. Allen, MD, MHS1; Gregg C. Fonarow, MD2; Li Liang, PhD3; Phillip J. Schulte, PhD3; Frederick A. Masoudi, MD, MSPH1; John S. Rumsfeld, MD, PhD1,4; P. Michael Ho, MD, PhD1,4; Zubin J. Eapen, MD, MHS3; Adrian F. Hernandez, MD, MHS3; Paul A. Heidenreich, MD, MHS5; Deepak L. Bhatt, MD, MPH6; Eric D. Peterson, MD, MPH3; Harlan M. Krumholz, MD, MS7 on behalf of the American Heart Association’s Get With The Guidelines Heart Failure (GWTG-HF) Investigators*

1Division of Cardiology and the Colorado Cardiovascular Outcomes Research Consortium, University of Colorado School of Medicine, Aurora, CO; 2University of California Los Angeles Medical Center, Los Angeles, CA; 3Duke Clinical Research Institute and Duke University Medical Center, Durham, NC; 4Veterans Affairs Medical Center, Denver, CO; 5Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA; 6Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA; 7Section of Cardiovascular Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Dept of Medicine, Yale School of Medicine; Department of Health Policy and Management, Yale School of Public Health; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT

*A complete list of the Get With The Guidelines Heart Failure (GWTG-HF) Investigators can be found in the online Supplemental Material

Address for Correspondence:
Larry A. Allen, MD, MHS
Division of Cardiology
University of Colorado School of Medicine
Academic Office 1, Room 7109
12631 E. 17th Avenue, Mail Stop B130
Aurora, CO 80045
Tel: 303-724-4713
Fax: 303-724-2094
E-mail: larry.allen@ucdenver.edu

Journal Subject Codes: Heart failure:[110] Congestive, Ethics and policy:[100] Health policy and outcome research
Abstract

Background—Guidelines for heart failure (HF) recommend prescription of guideline-directed medical therapy before hospital discharge; some of these therapies are included in publicly reported performance measures. The burden of new medications for individual patients has not been described.

Methods and Results—Get With The Guidelines-HF registry 2008-2013 collected prescribing, indications, and contraindications for angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB), beta-blockers (BB), aldosterone antagonists (AldA), hydralazine/isosorbide dinitrate (H/ISDN), and anticoagulants. The difference between a patient’s medication regimen at hospital admission and that recommended by HF quality measures at discharge was calculated. Among 158,922 patients from 271 hospitals with a primary discharge diagnosis of HF, initiation of ACEI/ARB was indicated in 18.1% of all patients (55.5% of those eligible at discharge were not receiving ACEI/ARB at admission), BB in 20.3% (50.5% of eligible), AldA in 24.1% (87.4% of eligible), H/ISDN in 8.6% (93.1% of eligible), and anticoagulant in 18.0% (58.0% of eligible). Cumulatively, 0.4% of patients were eligible for 5 new medication groups, 4.1% for 4, 9.4% for 3, 10.1% for 2, and 22.7% for 1; 15.0% were not eligible for new medications because of adequate prescribing at admission; and 38.4% were not eligible for any medications recommended by HF quality measures. Compared with newly indicated medications (mean 1.45±1.23), actual new prescriptions were lower (mean 1.16±1.00).

Conclusions—A quarter of patients hospitalized with HF need to start more than 1 medication to meet HF quality measures. Systems for addressing medication initiation and managing polypharmacy are central to HF transitional care.

Key words: heart failure, medication adherence, quality of health care, prescribing patterns, physician, medication therapy management
Introduction

Initiation and continuation of individual guideline-directed medical therapies prior to hospital discharge has been associated with improved adherence and clinical outcomes for patients with heart failure (HF).\textsuperscript{1-3} Reflective of these data, current clinical practice guidelines and hospital quality measures for HF include the following medications at discharge: 1) angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for HF with reduced ejection fraction (HFrEF), 2) beta-blocker (BB) for HFrEF, 3) aldosterone antagonists (AldA) for HFrEF, 4) hydralazine with isosorbide dinitrate (H/ISDN) for HFrEF among African-American patients, and 5) anticoagulants for those with atrial fibrillation.\textsuperscript{4,5} Quality measures are increasingly tied to hospital recognition, public reporting, and payments.\textsuperscript{6}

The vast majority of evidence for HF-related medical therapy derives from serial studies in which single medications were added to stable existing medical regimens, typically in an order dictated by scientific discovery rather than practical or physiological considerations. In the process of compiling this fragmented evidence, guidelines and quality measures in effect recommend that all of these medications be prescribed by the time of hospital discharge. The actual number of new medications recommended for individual patients at the time of hospital discharge by these comprehensive HF guidelines has not been well described. Given challenges around medication access and adherence,\textsuperscript{7} which can be compounded by new and increasing numbers of medications at the difficult time of hospital-to-home transitions,\textsuperscript{8} understanding the cumulative burden posed by guidelines and quality measures should help providers and health systems triage appropriate energy towards addressing newly recommended medications. Additionally, finding that current guidelines recommend for the simultaneous start of multiple medications in large numbers of patients would also fuel the need for research into
optimal timing and sequencing for such initiation. Therefore, we set out to quantify the
difference between the actual medication regimen at the time of admission and the recommended
medication regimen at the time of discharge according to HF guidelines and quality measures,
after accounting for documented contraindications/intolerance to such therapy.

Methods
Data Source
We conducted a cross-sectional study using data from the Get With The Guidelines®–Heart
Failure (GWTG-HF) voluntary quality improvement initiative. The design and validity of this
program’s methods and data capture have been published previously.9-11 Briefly, trained
personnel at each site abstract clinical data for all patients admitted with HF in compliance with
The Joint Commission and Centers for Medicare and Medicaid Services standards for quality
indicators. Variables collected include demographic and clinical characteristics, medical history,
medications, in-hospital treatments, in-hospital outcomes, and discharge disposition. Quintiles is
the data collection coordination center for the American Heart Association/American Stroke
Association GWTG programs. Their Internet-based Patient Management Tool performs checks
to ensure the completeness of the reported data. Additionally, data quality is monitored
independently and reports are generated to confirm the completeness and accuracy of submitted
data. Hospital data elements are collected for all enrolling hospitals from the American Hospital
Association database. Patient data are de-identified in accordance with the Health Insurance
Portability and Accountability Act and a random hospital identifier is used to identify the various
hospitals. All participating institutions were required to comply with local regulatory and privacy
guidelines and to secure institutional review board approval. Because data are used primarily at
the local site for quality improvement, sites were granted a waiver of informed consent under the common rule. The Duke Clinical Research Institute (Durham, North Carolina) serves as the data analysis center and has an agreement to analyze the aggregate de-identified data for research purposes.

**Patients and Hospitals**

We confined the current analysis to hospital admissions between April 1, 2008 and June 30, 2013 at hospitals fully participating in the GWTG-HF program. Fully participating hospitals were considered to be those with no more than 25% of history panel forms incomplete. We then excluded the following patients: those with inter-hospital transfer; those with documentation of comfort measures only; those with discharge destination missing, undetermined, hospice, or left against medical advice; and those who died in hospital.

Subgroups of interest were defined a priori. Prior history of HF was defined as medical history of HF or prior hospitalization for HF. Ischemic heart disease as the etiology for HF was defined as a medical history of coronary artery disease or myocardial infarction, or prior percutaneous coronary intervention or coronary artery bypass grafting. HFrEF was defined as most recent quantitative left ventricular ejection fraction (LVEF) <40% or qualitative LVEF moderately or severely reduced.

**Medication Quality Measures**

The GWTG-HF data collection form includes detailed capture of admission medications, documentation of LVEF, discharge medications, and contraindications to evidence-based therapies. Medication quality metrics defined by GWTG-HF during the study period were the following: 1) ACEI or ARB for LVEF <40%, 2) BB for LVEF <40%, 3) AldA for LVEF <35%, 4) H/ISDN for LVEF <40% among African-American patients, and 5) anticoagulants for those
with atrial fibrillation. If quantitative LVEF was missing, qualitative moderate or severe
reduction in LVEF replaced the reduced LVEF cutoffs. Contraindications and intolerances must
be selected from a drop-down list of approved reasons. For example, contraindications to AldA
include serum potassium >5 mmol, serum creatinine >2.5 mg/dL in men and >2.0 mg/dL in
women, and history of dialysis. A complete list of HF Achievement Measures and Quality
measures can be found online at http://www.heart.org/idc/groups/heart-
public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_310967.pdf. Details of
performance measures for Advanced Certification HF are at

Statistical Analysis

We calculated the difference between the patient’s medication regimen at the time of admission
and what would be recommended by current guidelines and quality measures at the time of
discharge, as well as the number of new HF medications actually prescribed at discharge. Patient
and hospital-level characteristics were selected based upon previous literature and clinical
criteria.\textsuperscript{12} Percentages and medians (25\textsuperscript{th}, 75\textsuperscript{th} percentiles) were reported to describe the
distribution of categorical and continuous variables. Chi-square and Wilcoxon two-sample tests
were used to compare characteristics between patients who had 2 or fewer new medications and
those who had 3 to 5 new medications to initiate at discharge.

Multivariable logistic regression was used to identify factors associated with increased or
decreased odds of a patient getting a recommended medication prescribed at discharge among
the patients who were eligible and not treated prior to discharge. Among the 5 potential options,
each medication class was considered as an opportunity such that a patient could have as many
as 5 responses or as few as one response: one for each newly recommended medication. The
generalized estimating equation method using exchangeable working correlation structure was used to account for correlation within patients when patients had more than one newly recommended medication. The model was also adjusted by the newly recommended medication profile (to account for differences in patient eligibility) and by the medication to which each observation applies (to account for differences in average prescribing rate for each of the medications). Patient-level variables included demographics (age, gender, race [Black, Hispanic ethnicity, other race, and White]), medical history (COPD, diabetes, hyperlipidemia, hypertension, PVD, CVA/TIA, ICD, anemia, pacemaker, dialysis chronic, renal insufficiency, depression, ischemic heart disease, smoking, prevalent heart failure, and atrial fibrillation/flutter), insurance status (Medicare, Medicaid, private/other, none), and vital signs (heart rate, systolic blood pressure at admission). Patients with gender missing were excluded. Other categorical variables with missing observations (all <5% missing) were imputed to the most common category. Body mass index and laboratory values at admission had more than 20% missing so were not included in modeling. Other continuous variables with missing observations were imputed to the medians. A p value ≤0.05 was considered statistically significant for all tests. All analyses were performed with SAS software version 9.2 (SAS Institute, Cary, NC).

Results

Hospital and Patient Characteristics

The final study sample included 158,922 patients from 271 hospitals discharged between April 1, 2008 and June 30, 2013. Among the patients eligible for at least one new medication, median age was 73 years, 60% were Caucasian, comorbidities were present in the majority of patients, and median length of stay was 4 days (Table 1). The majority of hospitals were academic, though
few performed heart transplants.

**Recommended Medication Initiation Burden**

ACEI/ARB initiation was indicated in 18.1% of all patients (55.5% of those eligible at discharge were not receiving ACEI/ARB at admission), BB in 20.3% (50.5% of eligible), AldA in 24.1% (87.4% of eligible), H/ISDN in 8.6% (93.1% of eligible), and anticoagulant in 18.0% (58.0% of eligible) (*Table 2*). Cumulatively, 13.9% of patients were eligible for 3 to 5 new medication groups, and 32.8% were eligible for 1 to 2 new medication groups; whereas 15.0% were not eligible for any new medications because of adequate prescribing prior to admission, and 38.4% were not eligible for any medications recommended by HF quality measures (99.0% of whom did not have reduced LVEF) (*Table 3*). The number of patients prescribed a medication at admission and discharged without the prescription was small, ranging from 0.68% for BB to 1.58% for anticoagulants.

**Common Combinations of Newly Recommended and Prescribed Medications**

The 5 most common combinations of newly recommended medications at discharge were anticoagulant only (23.5%), ACE/ARB+BB+AldA (12.0%), AldA only (6.1%), ACE/ARB+BB+AldA+H/ISDN (4.6%), and ACE/ARB+BB (4.4%). The combinations of medications that were newly prescribed paralleled the recommendations, albeit at lower frequencies.

**New Medication Recommendations by Patient Subgroups**

Among patients who were eligible for at least one new medication at discharge (N=97,888), 21.4% had no prior diagnosis of HF, 69.8% had LVEF <40%, and 55.6% had an ischemic etiology for HF. Patients without a prior HF diagnosis had a higher number of recommended medications to initiate compared with those with a prior HF diagnosis (mean 1.7±1.3 versus
1.3±1.2). Patients with LVEF <40% had a higher number of recommended medications to start compared to those with LVEF ≥40% (mean 1.8±1.3 versus 0.6±0.5). Patients without a history of ischemic heart disease had a higher number of newly recommended medications to start compared to those with ischemic heart disease (mean 1.56±1.27 versus 1.29±1.16).

**Prescribing of Newly Recommended Medications**

Compared with the number of new medications indicated (mean 1.45±1.23), the number of actual new prescriptions at discharge was lower (mean 1.16±1.00). ACEI/ARB was prescribed in 91.2% of those eligible but not receiving it prior to admission, BB prescribed in 94.1%, AldA in 27.2%, H/ISDN in 18.9%, and anticoagulant in 56.4%. In multivariable analysis, a prescription at discharge for the newly recommended medications was associated with the following patient characteristics: younger age, male, Caucasian, Medicare and non-Medicaid insured; history of hyperlipidemia, implantable cardioverter-defibrillator, or renal insufficiency; absent history of PVD, anemia, pacemaker, dialysis, depression, ischemic heart disease, and smoking; absence of reduced LVEF; and higher heart rate (Table 4).

**Discussion**

Among patients hospitalized with HF, 47% needed to start at least one new HF-related medication by discharge, 24% needed to start more than one, and 14% needed to start 3 or more in order to be in compliance with current HF guidelines and quality measures. These numbers do not include additional medications indicated for non-HF comorbidities. This provides the first large description of how layering evidence-based guideline recommendations can cumulatively lead to a high number of newly recommended medications for patients discharged after worsening HF. Other studies, including analyses from GWTG-HF, have assessed overall
indications for and prescribing of HF medications but have not distinguished between pre-existing and new use of these medications nor have they provided an assessment of total medication initiation burden. As quality measures are increasingly used in public reporting and payment decisions, evaluation of the cumulative burden created by process measures is crucial. While discrete recommendations may make sense in isolation, the simultaneous effect of multiple measures on patient well-being and care delivery should be factored into the overall design of reform efforts.

Research into the relative benefit of mass initiation of medications prior to discharge versus sequential initiation that extends into the ambulatory setting is needed. Staged medication initiation could be less overwhelming to patients in the difficult transition period and reduce the risk of hypotension and other side effects. Additionally, simultaneous addition of ACEI/ARB and AldA, which both have effects on kidney function and potassium handling, has not been well studied; fears of renal dysfunction and hyperkalemia may explain some of the underuse of AldA. However, these concerns must be balanced against research showing that inpatient initiation of individual medications is relatively safe and leads to higher use of these life-prolonging medications in the long-term. With current recommendations for 1-week post-discharge follow-up and increased attention on the transitional care period, the opportunity for sequential addition of medications exists. If staged initiation is considered to be preferable, the order in which these medications should be started in various populations is relatively unknown and also deserves further research.

As expected from the linkage between reduced LVEF and indications for many neurohormonal-antagonist therapies, patients with HFrEF had a relatively higher burden of recommended medications to initiate compared to patients with preserved LVEF. With the
common co-occurrence of HF and atrial fibrillation, HF medications and anticoagulation were also frequently co-recommended. Thus, certain patient populations, including those with multi-morbidity, are likely to be disproportionately affected by this layering of guideline recommendations and quality measures, and may warrant special attention.

Medication adherence research has focused primarily on continuation of medications; however, additions to medication regimens are typically more challenging for patients. Rates of primary nonadherence (i.e. never filling a medication) often exceed the rate of medication discontinuation. Thus, optimizing the process for getting patients onto medications in the first place may be one of the most critical aspects of adherence interventions. Therefore, transitional care systems that help ensure patients actually pick up and correctly start newly prescribed medications are likely to provide high value. Medication initiation strategies should be complemented by efforts to limit potential burdens and side effects. These necessarily complex medication regimens, particularly for HF/EF and multi-morbidity, demand multifaceted disease-management solutions that are yet-to-be perfected.

The study has several limitations. Hospitals voluntarily participating fully in GWTG-HF may not be representative of hospitals or HF patients in the United States; however, prior study has shown that patients in GWTG-HF are relatively similar to cross-sectional samples of national HF hospitalizations. Data were collected by chart review and so depend on the accuracy and completeness of documentation, particularly in terms of contraindications and intolerance. GWTG-HF collects data by site and hospitalization event, not by unique patients, such that the effect of recurrent hospitalizations for individual patients is not specifically accounted for in this analysis. Laboratory values are optional fields in GWTG-HF with a high rate of missingness, to an extent that we decided not to impute laboratory values or confine the analysis to patients with

10

11
complete laboratory values; however, sites were required to choose contraindications to medications from a menu of accepted reasons that included hyperkalemia and worsening renal function for ACEI/ARB and AldA, such that these variables do get incorporated into data capture. We do not have data on post-discharge adherence or outcomes that would have allowed for further investigation into the potential implications of multiple medication starts. Additionally, this analysis does not account for non-HF medications, which may significantly alter the complexity of discharge medication changes as narrowly reported here.

**Conclusions**

Nearly half of patients hospitalized with HF need to start at least one new medication, with 24% having indications for at least 2 medications and 14% for 3 or more medications, in order to comply with current HF guidelines and hospital quality measures. Systems for addressing medication initiation and managing polypharmacy are central to HF transitional care efforts.

**Funding Sources:** The Get With The Guidelines®–Heart Failure (GWTG-HF) program is provided by the American Heart Association. GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the American Heart Association Pharmaceutical Roundtable.” Dr. Allen is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL105896. Dr. Krumholz is supported by grant U01 HL105270-04 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association or the National Institutes of Health.

**Conflict of Interest Disclosures:** Dr. Allen reports receiving research grants from the National Institutes of Health and the American Heart Association; and serving as a consultant for Amgen,
Inc., Johnson & Johnson, and Novartis. Dr. Fonarow reports receiving research grants or other research support from National Institutes of Health, and the Agency for Healthcare Research and Quality; consulting for Bayer, Gambro, Novartis, Medtronic, and Johnson & Johnson; Dr. Fonarow holds the Eliot Corday Chair of Cardiovascular Medicine at UCLA and is also supported by the Ahmanson Foundation (Los Angeles, California). Dr. Masoudi reports no commercial relationships. Dr. Rumsfeld reports no commercial relationships. Dr. Ho serves as a consultant for Wellpoint, Inc. Dr. Eapen reports no conflicts. Dr. Hernandez reports receiving research support from Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novartis, and Portola Pharmaceuticals, and receiving honoraria from Amgen, Novartis and Janssen. Dr. Heidenreich reported no conflicts. Dr. Bhatt reports the following relationships: Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Get With The Guidelines Steering Committee; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor); Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, St. Jude Medical, The Medicines Company; Trustee: American College of Cardiology; Unfunded Research: FlowCo, PLx Pharma, Takeda. Dr. Eric Peterson reports grants and personal fees from Janssen, grants from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from AstraZeneca, outside the submitted work. Dr. Krumholz reports that he is the recipient of a research grant from Medtronic and Johnson and Johnson, through Yale University, to develop methods of clinical trial data sharing and is chair of a cardiac scientific advisory board for UnitedHealth. Drs. Hernandez and Peterson have made available online detailed listings of financial disclosures (http://www.dcri.duke.edu/research/coi.jsp).
References:


### Table 1. Patient and hospital characteristics for patients hospitalized with heart failure, overall and stratified by number of medications that guidelines recommend for initiation.

<table>
<thead>
<tr>
<th>Median (25th, 75th) or percent</th>
<th>Total</th>
<th>Not Eligible for Any HF Medications</th>
<th>Receiving All Indicated Medications at Admission</th>
<th>New Medications Recommended*</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=158,922</td>
<td>N=61,034</td>
<td>N=23,792</td>
<td>1-2 Meds N=52,171</td>
<td></td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td></td>
<td></td>
<td></td>
<td>3-5 Meds N=21,925</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>75 (63, 84)</td>
<td>75 (63, 85)</td>
<td>77 (66, 84)</td>
<td>75 (64, 84)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Female</td>
<td>48.3%</td>
<td>58.2%</td>
<td>46.4%</td>
<td>43.3%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Black</td>
<td>18.8%</td>
<td>18.0%</td>
<td>8.0%</td>
<td>17.7%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Medicare insured</td>
<td>60.2%</td>
<td>61.8%</td>
<td>61.0%</td>
<td>62.3%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atrial fibrillation, chronic</td>
<td>35.1%</td>
<td>12.7%</td>
<td>64.2%</td>
<td>47.8%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>COPD or asthma</td>
<td>31.4%</td>
<td>33.4%</td>
<td>33.7%</td>
<td>30.6%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>44.1%</td>
<td>49.1%</td>
<td>45.1%</td>
<td>41.8%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>49.7%</td>
<td>49.6%</td>
<td>56.0%</td>
<td>50.7%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>78.5%</td>
<td>82.1%</td>
<td>79.9%</td>
<td>77.3%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>12.2%</td>
<td>12.6%</td>
<td>14.2%</td>
<td>12.4%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CVA or TIA</td>
<td>15.1%</td>
<td>15.0%</td>
<td>17.7%</td>
<td>15.1%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Anemia</td>
<td>20.0%</td>
<td>24.4%</td>
<td>20.6%</td>
<td>18.4%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Dialysis, chronic</td>
<td>4.1%</td>
<td>6.3%</td>
<td>3.6%</td>
<td>3.1%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>22.8%</td>
<td>26.0%</td>
<td>23.8%</td>
<td>22.1%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Depression</td>
<td>10.7%</td>
<td>11.9%</td>
<td>12.1%</td>
<td>10.0%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking</td>
<td>16.5%</td>
<td>15.1%</td>
<td>12.1%</td>
<td>16.2%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Prevalent heart failure</td>
<td>69.8%</td>
<td>64.0%</td>
<td>78.6%</td>
<td>73.8%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>17.7%</td>
<td>15.4%</td>
<td>24.6%</td>
<td>18.9%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ICD</td>
<td>10.3%</td>
<td>2.7%</td>
<td>13.6%</td>
<td>14.8%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>LVEF &lt;40% or moderately to</td>
<td>43.4%</td>
<td>1.2%</td>
<td>48.1%</td>
<td>67.0%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>severely reduced</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m2</td>
<td>28.1 (23.7, 34.2)</td>
<td>29.2 (24.2, 36.2)</td>
<td>27.8 (23.7, 33.5)</td>
<td>27.3 (23.4, 32.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>82 (70, 97)</td>
<td>80 (69, 93)</td>
<td>80 (70, 94)</td>
<td>84 (71, 99)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>140 (121, 161)</td>
<td>148 (128, 172)</td>
<td>135 (117, 154)</td>
<td>135 (117, 155)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Length of stay, days</td>
<td>4 (3, 6)</td>
<td>4 (3, 6)</td>
<td>4 (3, 6)</td>
<td>4 (3, 7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hospital Characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of beds</td>
<td>400 (270, 601)</td>
<td>394 (258, 593)</td>
<td>410 (250, 610)</td>
<td>405 (280, 601)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Academic status</td>
<td>66.5%</td>
<td>63.6%</td>
<td>64.3%</td>
<td>68.3%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Heart transplants performed</td>
<td>8.8%</td>
<td>7.1%</td>
<td>10.4%</td>
<td>9.9%</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

HF indicates heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; TIA, transient ischemic attack; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; and BMI, body mass index; * The population for the multivariable analysis used the patients with new medication recommended (N=74096).
Table 2. Eligibility, baseline use at admission, recommended new prescriptions, prescription at discharge, and actual increase for individual medication

<table>
<thead>
<tr>
<th>Medication</th>
<th>Eligible, n (of all patients, %)</th>
<th>Use prior to admission, n (of eligible patients, %)</th>
<th>Newly recommended, n (of eligible patients, %)</th>
<th>Total Prescribed at discharge*, n (of eligible patients, %)</th>
<th>Newly prescribed at discharge, n (of newly recommended for patients, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEI/ARB</td>
<td>51,847 (32.62)</td>
<td>23,059 (44.48)</td>
<td>28,788 (55.52)</td>
<td>48,842 (94.20)</td>
<td>26,257 (91.21)</td>
</tr>
<tr>
<td>βB</td>
<td>63,878 (40.19)</td>
<td>31,595 (49.46)</td>
<td>32,283 (50.54)</td>
<td>61,532 (96.33)</td>
<td>30,370 (94.07)</td>
</tr>
<tr>
<td>Aldosterone antagonist</td>
<td>43,780 (27.55)</td>
<td>5,532 (12.64)</td>
<td>38,248 (87.36)</td>
<td>15,353 (35.07)</td>
<td>10,040 (27.19)</td>
</tr>
<tr>
<td>H/ISDN</td>
<td>14,742 (9.28)</td>
<td>1,015 (6.89)</td>
<td>13,727 (93.11)</td>
<td>3,480 (23.61)</td>
<td>2,596 (18.91)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>49,304 (31.02)</td>
<td>20,709 (42.00)</td>
<td>28,595 (58.00)</td>
<td>36,061 (73.14)</td>
<td>16,133 (56.42)</td>
</tr>
</tbody>
</table>

ACEI/ARB indicates angiotensin converting enzyme inhibitors/angiotensin receptor blockers; βB, beta-blockers; and H/ISDN, hydralazine/isosorbide dinitrate. *Includes continuing prescription (with use prior to admission) and newly prescribed.

Table 3. Cumulative number of medications patients were to initiate based on heart failure measures, overall and by left ventricular ejection fraction

<table>
<thead>
<tr>
<th>Number of Medications Patient Eligible to Initiate</th>
<th>All Patients*</th>
<th>LVEF &lt;40% or moderate to severe dysfunction</th>
<th>LVEF &gt;=40% or normal to mild dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of Patients</td>
<td>Percent of All Patients</td>
<td>Number of Patients</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>5</td>
<td>566</td>
<td>0.4%</td>
<td>566</td>
</tr>
<tr>
<td>4</td>
<td>6,496</td>
<td>4.1%</td>
<td>6,496</td>
</tr>
<tr>
<td>3</td>
<td>14,863</td>
<td>9.4%</td>
<td>14,863</td>
</tr>
<tr>
<td>2</td>
<td>16,067</td>
<td>10.1%</td>
<td>16,067</td>
</tr>
<tr>
<td>1</td>
<td>36,104</td>
<td>22.7%</td>
<td>18,884</td>
</tr>
<tr>
<td>0</td>
<td>84,826</td>
<td>53.3%</td>
<td>12,157</td>
</tr>
</tbody>
</table>

* All patients include the 2% of the cohort with missing LVEF / systolic function.
### Table 4. Multivariable model for factors associated with prescribed medication among the newly recommended medications from admission to discharge

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 10 years)</td>
<td>0.82 (0.81, 0.83)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Female (vs. male)</td>
<td>0.96 (0.93, 0.99)</td>
<td>0.0039</td>
</tr>
<tr>
<td>Race: Black (vs. White)</td>
<td>0.90 (0.83, 0.99)</td>
<td>0.022</td>
</tr>
<tr>
<td>Hispanic ethnicity (vs. Not)</td>
<td>0.78 (0.74, 0.83)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Race: Other (vs. White)</td>
<td>0.79 (0.75, 0.83)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Insurance: None (vs. private/HMO/other insurance)</td>
<td>1.01 (0.94, 1.08)</td>
<td>0.87</td>
</tr>
<tr>
<td>Insurance: Medicaid (vs. private/HMO/other insurance)</td>
<td>0.87 (0.82, 0.92)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Insurance: Medicare (vs. private/HMO/other insurance)</td>
<td>1.11 (1.07, 1.15)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PMHX: Pulmonary</td>
<td>0.97 (0.93, 1.00)</td>
<td>0.055</td>
</tr>
<tr>
<td>PMHX: Diabetes</td>
<td>1.01 (0.98, 1.04)</td>
<td>0.48</td>
</tr>
<tr>
<td>PMHX: Hyperlipidemia</td>
<td>1.14 (1.10, 1.17)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PMHX: Hypertension</td>
<td>1.01 (0.98, 1.05)</td>
<td>0.50</td>
</tr>
<tr>
<td>PMHX: PVD</td>
<td>0.93 (0.89, 0.98)</td>
<td>0.0074</td>
</tr>
<tr>
<td>PMHX: CVA/TIA</td>
<td>1.03 (0.99, 1.08)</td>
<td>0.14</td>
</tr>
<tr>
<td>PMHX: ICD</td>
<td>1.09 (1.04, 1.14)</td>
<td>0.0003</td>
</tr>
<tr>
<td>PMHX: Anemia</td>
<td>0.95 (0.91, 0.99)</td>
<td>0.023</td>
</tr>
<tr>
<td>PMHX: Pacemaker</td>
<td>0.94 (0.90, 0.98)</td>
<td>0.0084</td>
</tr>
<tr>
<td>PMHX: Dialysis Chronic</td>
<td>0.51 (0.46, 0.57)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PMHX: Renal insufficiency</td>
<td>1.08 (1.04, 1.13)</td>
<td>0.0002</td>
</tr>
<tr>
<td>PMHX: Depression</td>
<td>0.89 (0.85, 0.94)</td>
<td>0.0001</td>
</tr>
<tr>
<td>PMHX: Smoker</td>
<td>0.95 (0.91, 0.99)</td>
<td>0.012</td>
</tr>
<tr>
<td>Prior HF history (vs. new HF)</td>
<td>1.01 (0.98, 1.05)</td>
<td>0.48</td>
</tr>
<tr>
<td>LVSD (vs. not)</td>
<td>0.51 (0.46, 0.56)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atrial fib, chronic/recur history or during this hospitalization</td>
<td>0.97 (0.91, 1.03)</td>
<td>0.27</td>
</tr>
<tr>
<td>Systolic BP at admission (per 10 units)</td>
<td>1.00 (0.99, 1.00)</td>
<td>0.22</td>
</tr>
<tr>
<td>Heart rate at admission (per 10 units)</td>
<td>1.03 (1.02, 1.04)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

OR indicates odds ratio; CI, confidence interval; HMO indicates health maintenance organization; PMHX, patient medical history; PVD, peripheral vascular disease; CVA, cerebrovascular accident; TIA, transient ischemic attack; ICD, implantable cardioverter-defibrillator; HF, heart failure; LVSD, left ventricular systolic dysfunction; and BP, blood pressure.
Medication Initiation Burden Required to Comply with Heart Failure Guideline Recommendations and Hospital Quality Measures


on behalf of the American Heart Association's Get With The Guidelines Heart Failure (GWTG-HF) Investigators

Circulation. published online August 27, 2015;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2015/08/27/CIRCULATIONAHA.115.014281

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2015/08/27/CIRCULATIONAHA.115.014281.DC1
http://circ.ahajournals.org/content/suppl/2016/12/26/CIRCULATIONAHA.115.014281.DC2

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

Roster of clinician volunteers for Get with the Guidelines Heart Failure.

Clyde Yancy, MD
Gregg Fonarow, MD
Paul Heidenreich, MD
Adrian Hernandez, MD
Ileana Pina, MD
Nancy Albert, PhD, CCNS
Warren Laskey, MD
David Whellan, MD
Deepak Bhatt, MD
Larry Allen, MD
Adam DeVore, MD
Srinivas Murali, MD
Lee Goldberg, MD, Heart Failure Society of America representative
Pam Peterson, MD, Heart Failure Society of America representative
Debra Moser, MD, Heart Failure Society of America representative
Nita Reigle, MSN, ACNP, American Association of Heart Failure Nurses representative
심부전 약물치료 가이드라인과 병원의 질 평가지표를 준수하기 위해서는 새로운 약제를 시작해야 하는 부담이 요구된다

박 혼 준 교수 가톨릭대학교 서울성모병원 순환기내과

초록

배경
심부전 가이드라인은 환자가 퇴원하기 전에 가이드라인에 기반한 약물처방을 권장한다. 이러한 치료요법은 국가기준이 공개적으로 보고하는 수행평가지표들에 포함되어 있다. 그러나 개별 환자에서 새로운 약물들이 주는 부담에 대해서는 기술된 바가 없다.

방법 및 결과
2008년부터 2013년까지 Get With The Guidelines-Heart Failure(GWTG-HF) 연구에 등록된 자료를 이용하였으며, 안지오텐신 전환효소 저해제 또는 수용체 길항제, 베타차단제, 알도스테론 길항제, 하이드랄라진/이소비드 디나이트레이트 (hydralazine/isosorbide dinitrate) 그리고 항응고제에 대한 처방, 적응증, 금기증의 특성을 분석하였다. 환자가 입원한 당시 처방 받은 약제들과 퇴원 시에 심부전 질 평가지표에 의해 처방 받은 약제들 간의 차이를 계산하였다. 전국 271개 병원에 의한 심부전으로 진단된 158,922명의 환자에서 안지오텐신 전환효소 저해제 또는 수용체 길항제를 시작한 환자는 18.1%였다(55.5%), 퇴원 시 안지오텐신 전환효소 저해제 또는 수용체 길항제에 적응증이 되는 이들 환자의 55.5%가 퇴원 당시에는 본 약물들을 투여 받지 않았다. 그리고 베타차단제는 20.3%(50.5%), 알도스테론 길항제는 24.1%(87.4%), 하이드랄라진/이소비드 디나이트레이트는 6.6%(93.1%), 항응고제는 18.0%(58.0%)였다. 수술적 표면, 0.4%의 환자가 다섯 가지 약물에 새롭게 적응증이 되었으며, 그 외에 4.1%가 네 가지 약물, 9.4%가 세 가지 약물, 10.1%가 두 가지 약물, 22.7%가 한 가지 약물에 새롭게 적응증이 되었다. 반면, 15%의 환자는 입원 당시의 적절한 처방으로 새로운 약물치료에 적응증이 되지 않았으며, 38.4%의 환자는 심부전 질 평가지표를 기준으로 적응증이 되는 약물이 없었다. 새롭게 적응증이 되는 약물에 비해, 실제로 새롭게 처방된 약물은 적었다(1.45±1.23 vs. 1.16±1.00).

결론
심부전으로 입원하는 환자의 25%는 심부전 질 평가지표를 만족시키기 위해서 한 가지 이상의 약물을 새롭게 시작해야 한다. 약물 시작 여부를 결정하고 다제투여를 관리하는 체계는 심부전으로 입원하는 환자의 치료에 중요한 부분이다.